Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 300.00
Change Today 0.00 / 0.00%
Volume 0.0
KDST On Other Exchanges
Tel Aviv
As of 3:15 AM 08/2/15 All times are local (Market data is delayed by at least 15 minutes).

kadimastem ltd (KDST) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/14 - $404.00
52 Week Low
06/9/15 - $170.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KADIMASTEM LTD (KDST)

Related News

No related news articles were found.

kadimastem ltd (KDST) Related Businessweek News

View More BusinessWeek News

kadimastem ltd (KDST) Details

Kadimastem Ltd., a regenerative medicine company, focuses on the development and commercialization of stem cell-based therapeutics primarily for diabetes and neurodegenerative disorders. Its products include human pluripotent stem cell-based solutions to replace the exhausting daily blood glucose monitoring and insulin injections in diabetes patients; and stem cell-based therapeutic solutions for amyotrophic lateral sclerosis, spinal cord injury, and multiple sclerosis diseases. The company was founded in 2009 and is based in Nes-Ziona, Israel.

Founded in 2009

kadimastem ltd (KDST) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: 663.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: 455.0K
Compensation as of Fiscal Year 2014.

kadimastem ltd (KDST) Key Developments

Kadimastem Ltd., Special/Extraordinary Shareholders Meeting, Feb 11, 2015

Kadimastem Ltd., Special/Extraordinary Shareholders Meeting, Feb 11, 2015., at 10:00 Israel Standard Time.

Kadimastem Approaches FDA Regarding its ALS Treatment

Kadimastem announced that it approached the FDA regarding the cellular treatment it is developing for ALS. This is the initial approach the company is making to the FDA. In the framework of talks with the FDA, Kadimastem intends to consolidate a preliminary outline for its continuing trials for this indication. Recently, the company reported positive results in a pre-clinical trial it conducted. In the trial, the efficacy of injecting support cells (astrocytes), produced by the company in a unique technology, into the spinal fluid of ALS model mice, was tested. This model is highly significant in predicting the treatment's activity in humans. The results of the trial showed an increased life expectancy in the mice treated, as well as a significant improvement of their motor (muscle) function, compared to the untreated mice. The efficacy of the treatment was also demonstrated in other indices indicating a delay in disease onset. Injections into the spinal fluid are standard procedure performed routinely in hospitals around the world. The company found that injections into the spinal fluid enable the even dispersion of cells throughout the central nervous system, thereby establishing the method of cell penetration in future treatment of patients.

Kadimastem Ltd. Signs Cooperation Agreement with Merck Serono for Scanning Drugs

Kadimastem Ltd. announced that it had signed a cooperation agreement with Merck Serono for scanning drugs as potential treatments for multiple sclerosis and other neurodegenerative diseases. Kadimastem will use its unique platform for Merck Serono, Merck's biopharmaceutical division, in the scanning of potential new drugs. Kadimasten has developed technologies for stem cell differentiation for oligodendrocytes, cells required by the brain in order to produce myelin for insulation of nerve fibers. In multiple sclerosis, oligodendrocytes are destroyed by the immune system. Kadimasten also has the capability to generate astrocytes from stem cells. Astrocytes are support cells that have been found to be involved in neurodegenerative diseases. Soon after the signing of the contract, Merck will make an initial payment to Kadimasten; additional payments will be paid according to milestones that have been set. The deal is consistent with Kadimasten's strategy of generating revenue in the short term and tightening its connections with major international pharmaceutical firms for drug scanning projects.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KDST:IT 300.00 0.00

KDST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KDST.
View Industry Companies

Industry Analysis


Industry Average

Valuation KDST Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KADIMASTEM LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at